Vladimir Tesar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/948529/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	13.7	2,087
2	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 360, 1395-1407.	27.0	1,781
3	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	27.0	1,471
4	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
5	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine, 2003, 349, 36-44.	27.0	1,239
6	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
7	Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1103-1112.	6.1	923
8	Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
9	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	27.0	820
10	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis. Annals of Internal Medicine, 2009, 150, 670.	3.9	790
11	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
12	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine, 2011, 365, 1886-1895.	27.0	544
13	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA - Journal of the American Medical Association, 2010, 304, 2381.	7.4	524
14	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	21.4	505
15	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 622-631.	27.0	465
16	2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 713-723.	0.9	463
17	Avacopan for the Treatment of ANCA-Associated Vasculitis. New England Journal of Medicine, 2021, 384, 599-609.	27.0	461
18	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology: JASN, 2017, 28, 2756-2767.	6.1	448

#	Article	IF	CITATIONS
19	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2017, 377, 1930-1942.	27.0	420
20	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	13.7	408
21	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney International, 2014, 86, 828-836.	5.2	373
22	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases, 2012, 71, 955-960.	0.9	348
23	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
24	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genetics, 2012, 8, e1002765.	3.5	301
25	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet, The, 2017, 389, 2117-2127.	13.7	278
26	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 687-696.	11.4	221
27	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases, 2015, 74, 1178-1182.	0.9	217
28	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
29	The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrology Dialysis Transplantation, 2004, 19, 3040-3049.	0.7	187
30	Corticosteroids in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2248-2258.	6.1	187
31	Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrology Dialysis Transplantation, 2013, 28, 1839-1844.	0.7	177
32	Advanced glycoxidation end products in chronic diseases—clinical chemistry and genetic background. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 579, 37-46.	1.0	167
33	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Annals of the Rheumatic Diseases, 2019, 78, 399-405.	0.9	165
34	High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrology Dialysis Transplantation, 2006, 21, 3115-3121.	0.7	164
35	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	12.8	160
36	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival,Âfrequency of relapse, and outcomes compared to single-seropositive patients. Kidney International, 2017, 92, 693-702.	5.2	154

#	Article	IF	CITATIONS
37	Soluble Receptor for Advanced Glycation End Products in Patients With Decreased Renal Function. American Journal of Kidney Diseases, 2006, 47, 406-411.	1.9	146
38	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
39	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
40	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, 15873.	2.3	131
41	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology: JASN, 2018, 29, 2745-2754.	6.1	128
42	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
43	Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. American Journal of Nephrology, 2016, 43, 1-19.	3.1	106
44	Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrology Dialysis Transplantation, 2017, 32, gfw070.	0.7	103
45	Lupus nephritis management guidelines compared. Nephrology Dialysis Transplantation, 2016, 31, 904-913.	0.7	97
46	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.9	93
47	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	1.9	89
48	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
49	Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal. Kidney and Blood Pressure Research, 2019, 44, 298-330.	2.0	80
50	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1128-1135.	4.5	75
51	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2009, 68, 1125-1130.	0.9	72
52	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatric Nephrology, 2017, 32, 139-150.	1.7	71
53	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 393-399.	5.6	71
54	Receptor for advanced glycation end products–soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2007, 22, 2020-2026.	0.7	68

#	Article	IF	CITATIONS
55	Markers for the progression of IgA nephropathy. Journal of Nephrology, 2016, 29, 535-541.	2.0	66
56	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009.	0.7	66
57	A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrology Dialysis Transplantation, 2006, 22, 179-186.	0.7	64
58	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 315-325.	1.9	62
59	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 400-406.	5.6	62
60	Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. Nephron, 2016, 132, 15-24.	1.8	60
61	Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 3404-3413.	6.1	60
62	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	1.9	57
63	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2014, 64, 40-48.	1.9	55
64	Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994–2011. Journal of Nephrology, 2015, 28, 39-49.	2.0	55
65	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1571-1576.	4.5	53
66	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association–European Dialysis and Transplant Association Registry. American Journal of Kidney Diseases, 2015, 66, 613-620.	1.9	52
67	Glycoxidation and inflammation in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2577-2581.	0.7	47
68	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.9	47
69	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of <i>S</i> equential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. CKJ: Clinical Kidney Journal, 2015, 8, 503-510.	2.9	47
70	Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1103-1111.	4.5	47
71	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. Kidney International, 2021, 99, 1179-1188.	5.2	47
72	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis and Rheumatology, 2019, 71, 411-419.	5.6	45

#	Article	IF	CITATIONS
73	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Kidney International Reports, 2018, 3, 1039-1049.	0.8	41
74	Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. American Journal of Nephrology, 2015, 41, 296-301.	3.1	39
75	Tissue ischemia worsens during hemodialysis in end-stage renal disease patients. Journal of Vascular Access, 2017, 18, 47-51.	0.9	39
76	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
77	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrology Dialysis Transplantation, 2021, 36, 1160-1168.	0.7	38
78	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
79	Why Target the Gut to Treat IgA Nephropathy?. Kidney International Reports, 2020, 5, 1620-1624.	0.8	37
80	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrology Dialysis Transplantation, 2021, 37, 42-52.	0.7	36
81	Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease. BioMed Research International, 2015, 2015, 1-8.	1.9	35
82	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 436-447.	6.1	34
83	Treatment of proliferative lupus nephritis: a slowly changing landscape. Nature Reviews Nephrology, 2011, 7, 96-109.	9.6	33
84	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Journal of Nephrology, 2016, 29, 195-201.	2.0	33
85	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	5.2	32
86	Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrology Dialysis Transplantation, 2014, 29, 1728-1732.	0.7	31
87	The retrospective analysis of 343 Czech patients with IgA nephropathyone centre experience. Nephrology Dialysis Transplantation, 2012, 27, 1492-1498.	0.7	29
88	Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PLoS ONE, 2019, 14, e0212254.	2.5	29
89	Lower Retinol Levels as an Independent Predictor of Mortality in Long-term Hemodialysis Patients: A Prospective Observational Cohort Study. American Journal of Kidney Diseases, 2010, 56, 513-521.	1.9	28
90	Avacopan in the treatment of ANCA-associated vasculitis. Expert Opinion on Investigational Drugs, 2018, 27, 491-496.	4.1	28

#	Article	IF	CITATIONS
91	Lupus Nephritis: A Different Disease in European Patients?. Kidney Diseases (Basel, Switzerland), 2015, 1, 110-118.	2.5	27
92	Outcome of Thirty Patients with ANCA-Associated Renal Vasculitis Admitted to the Intensive Care Unit. Renal Failure, 2008, 30, 890-895.	2.1	25
93	Intracellular Cytokine Production in ANCA-associated Vasculitis: Low Levels of Interleukin-10 in Remission Are Associated with a Higher Relapse Rate in the Long-term Follow-up. Archives of Medical Research, 2009, 40, 276-284.	3.3	25
94	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. BMJ Open, 2021, 11, e047245.	1.9	25
95	Framework for establishing integrated kidney care programs in low- and middle-income countries. Kidney International Supplements, 2020, 10, e19-e23.	14.2	24
96	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney International, 2021, 99, 671-685.	5.2	24
97	Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. Frontiers in Immunology, 2021, 12, 593288.	4.8	24
98	Hemodialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 326-335.e1.	1.9	24
99	Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 2022, 37, 1099-1108.	0.7	24
100	HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 1-10.	0.6	24
101	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
102	NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients. Inflammation Research, 2017, 66, 369-378.	4.0	23
103	Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney International Supplements, 2020, 10, e63-e71.	14.2	23
104	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 829-838.	6.1	23
105	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1684-1687.e10.	2.9	22
106	Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study. Disease Markers, 2016, 2016, 1-9.	1.3	21
107	Emerging Modes of Treatment of IgA Nephropathy. International Journal of Molecular Sciences, 2020, 21, 9064.	4.1	21
108	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 2022, 37, 1400-1410.	0.7	21

#	Article	IF	CITATIONS
109	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Research and Therapy, 2015, 17, 371.	3.5	20
110	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrology Dialysis Transplantation, 2019, 34, 301-308.	0.7	20
111	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology, 2021, 60, 4654-4661.	1.9	20
112	Pregnancy-Associated Plasma Protein A as an Independent Mortality Predictor in Long-Term Hemodialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 192-201.	2.0	19
113	Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study. BMC Nephrology, 2013, 14, 245.	1.8	19
114	Addition of ETA receptor blockade increases renoprotection provided by renin–angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. Life Sciences, 2014, 118, 297-305.	4.3	19
115	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	4.5	19
116	Limitations of Standard Immunosuppressive Treatment in ANCA-Associated Vasculitis and Lupus Nephritis. Nephron Clinical Practice, 2015, 128, 205-215.	2.3	19
117	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
118	Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2019, 34, 587-596.	0.7	19
119	Recent Progress in the Pathogenesis of Nephrotic Proteinuria. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 139-220.	6.1	18
120	Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. American Journal of Kidney Diseases, 2019, 73, 184-193.	1.9	18
121	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 79-87.	4.5	18
122	Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease. Advances in Clinical Chemistry, 2021, 105, 141-212.	3.7	17
123	Resting energy expenditure and thermal balance during isothermic and thermoneutral haemodialysis heat production does not explain increased body temperature during haemodialysis. Nephrology Dialysis Transplantation, 2007, 22, 3553-3560.	0.7	16
124	Genetic Predisposition to Advanced Glycation End Products Toxicity Is Related to Prognosis of Chronic Hemodialysis Patients. Kidney and Blood Pressure Research, 2010, 33, 30-36.	2.0	16
125	Associations of Serum Levels of Advanced Glycation end Products with Nutrition Markers and Anemia in Patients with Chronic Kidney Disease. Renal Failure, 2011, 33, 131-137.	2.1	16
126	The effect of highâ€flow arteriovenous fistulas on systemic haemodynamics and brain oxygenation. ESC Heart Failure, 2021, 8, 2165-2171.	3.1	16

#	Article	IF	CITATIONS
127	Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. Nephrology Dialysis Transplantation, 2011, 26, 573-579.	0.7	15
128	The coincidence of IgA nephropathy and Fabry disease. BMC Nephrology, 2013, 14, 6.	1.8	15
129	Nephrology in the Eastern and Central European region: challenges and opportunities. Kidney International, 2019, 96, 287-290.	5.2	15
130	English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. Kidney International, 2020, 98, 1352-1353.	5.2	15
131	Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. International Journal of Molecular Sciences, 2022, 23, 3317.	4.1	15
132	New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. Journal of Clinical Medicine, 2022, 11, 2810.	2.4	15
133	Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease. Kidney and Blood Pressure Research, 2011, 34, 457-464.	2.0	14
134	Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study. Arthritis Research and Therapy, 2016, 18, 168.	3.5	14
135	Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?. Journal of Nephrology, 2020, 33, 307-316.	2.0	14
136	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. Nephrology Dialysis Transplantation, 2020, 35, 920-925.	0.7	14
137	Rokitansky and his first description of polyarteritis nodosa. Journal of Nephrology, 2004, 17, 172-4.	2.0	14
138	Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2014, 30 Suppl 1, i159-63.	0.7	13
139	Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. American Journal of Nephrology, 2018, 48, 465-471.	3.1	13
140	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
141	EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding) Tj ETQq1 1 0.784 Clinical Biochemistry, 2012, 45, 556-560.	314 rgBT 1.9	/Overlock 10 12
142	Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. Atherosclerosis, 2014, 236, 263-269.	0.8	12
143	Belimumab in the management of systemic lupus erythematosus – an update. Expert Opinion on Biological Therapy, 2017, 17, 901-908.	3.1	12
144	Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. Expert Opinion on Biological Therapy, 2018, 18, 989-996.	3.1	12

#	Article	IF	CITATIONS
145	Mass spectrometry-based proteomic exploration of the small urinary extracellular vesicles in ANCA-associated vasculitis in comparison with total urine. Journal of Proteomics, 2021, 233, 104067.	2.4	12
146	Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients. International Journal of Cardiology, 2021, 334, 148-153.	1.7	12
147	Plasma exchange in ANCA-associated vasculitis: the pro position. Nephrology Dialysis Transplantation, 2021, 36, 227-231.	0.7	12
148	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	11
149	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. Nephrology Dialysis Transplantation, 2021, 36, 1758-1760.	0.7	11
150	Soluble cytokine receptors in renal vasculitis and lupus nephritis. Medical Science Monitor, 2002, 8, BR24-9.	1.1	11
151	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 2190-2200.	0.7	11
152	Complement Inhibition in ANCA-Associated Vasculitis. Frontiers in Immunology, 0, 13, .	4.8	11
153	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 329-349.	2.0	10
154	Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic. BMC Medical Genetics, 2018, 19, 147.	2.1	10
155	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, 23-35.	2.9	10
156	The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrology Dialysis Transplantation, 2023, 38, 551-561.	0.7	10
157	Effect of Hemodiafiltration on Pregnancy-Associated Plasma Protein A (PAPP-A) and Related Parameters. Renal Failure, 2006, 28, 715-721.	2.1	9
158	Pregnancy-associated plasma protein A: spotlight on kidney diseases. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1183-90.	2.3	9
159	IgA Nephropathy in Czech Patients - Are We Able Reliably Predict the Outcome?. Kidney and Blood Pressure Research, 2014, 39, 555-562.	2.0	9
160	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives. Kidney and Blood Pressure Research, 2020, 45, 157-165.	2.0	9
161	Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation. Frontiers in Immunology, 2021, 12, 726215.	4.8	9
162	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. Nephrology Dialysis Transplantation, 2021, 37, 159-167.	0.7	9

#	Article	IF	CITATIONS
163	Early Identification of CKD—A Scoping Review of the Global Populations. Kidney International Reports, 2022, 7, 1341-1353.	0.8	9
164	Does Renal Function Influence Plasma Levels of Advanced Glycation and Oxidation Protein Products in Patients with Chronic Rheumatic Diseases Complicated by Secondary Amyloidosis?. Kidney and Blood Pressure Research, 2007, 30, 1-7.	2.0	8
165	Mycophenolate Mofetil in Low Doses Stabilizes and Improves Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Lupus Nephritis. Archives of Medical Research, 2008, 39, 115-119.	3.3	8
166	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. Kidney International Reports, 2021, 6, 2903-2907.	0.8	8
167	LONG TERM TREATMENT OF IgA NEPHROPATHY WITH CYCLOSPORINE A. Renal Failure, 2000, 22, 55-62.	2.1	7
168	MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	7
169	Chronic kidney disease and pregnancy outcomes. Scientific Reports, 2021, 11, 21299.	3.3	7
170	The management of membranous nephropathy—an update. Nephrology Dialysis Transplantation, 2022, 37, 1033-1042.	0.7	7
171	Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. Nephrology Dialysis Transplantation, 2022, 37, 1195-1197.	0.7	7
172	Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 711-712.	4.5	6
173	FRI0193â€2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
174	Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. European Journal of Hospital Pharmacy, 2019, 26, 210-213.	1.1	6
175	Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1519-1521.	4.5	6
176	SGLT2 inhibitors in non-diabetic kidney disease. Advances in Clinical and Experimental Medicine, 2022, 31, 105-107.	1.4	6
177	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. Kidney Medicine, 2022, 4, 100457.	2.0	6
178	Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis – still of value for our patients?. Expert Opinion on Pharmacotherapy, 2015, 16, 1683-1702.	1.8	5
179	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Journal of Rheumatology, 2020, 47, 580-588.	2.0	5
180	Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. Medical Science Monitor, 2002, 8, BR69-74.	1.1	5

#	Article	IF	CITATIONS
181	Immunotactoid glomerulonephritis as a cause of acute renal failure. Nephrology Dialysis Transplantation, 2004, 19, 1016-1017.	0.7	4
182	Secondary Membranous Nephropathy—One Center Experience. Renal Failure, 2005, 27, 397-402.	2.1	4
183	Rare transformation in repeat renal biopsies suggests a different pathogenesis of segmental and global lesions in proliferative lupus nephritis. Nephrology Dialysis Transplantation, 2013, 28, 2929-2932.	0.7	4
184	Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach. American Journal of Nephrology, 2017, 46, 93-95.	3.1	4
185	The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin AÂnephropathy and associated with defective CD46 expression. Nephrology Dialysis Transplantation, 2021, 36, 1389-1398.	0.7	4
186	Analysis of microRNAs in Small Urinary Extracellular Vesicles and Their Potential Roles in Pathogenesis of Renal ANCA-Associated Vasculitis. International Journal of Molecular Sciences, 2022, 23, 4344.	4.1	4
187	Peritoneal dialysis in the elderly–is its underutilization justified?. Nephrology Dialysis Transplantation, 2010, 25, 3473-3476.	0.7	3
188	ANCA-Associated Renal Vasculitis - An Update. Contributions To Nephrology, 2013, 181, 216-228.	1.1	3
189	Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients. Clinical Biochemistry, 2014, 47, 578-583.	1.9	3
190	Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?. Nephrology Dialysis Transplantation, 2015, 30, 1088-1090.	0.7	3
191	Urine sCD163: a window onto glomerular inflammation. Nephrology Dialysis Transplantation, 2016, 31, 1970-1972.	0.7	3
192	Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis. Kidney and Blood Pressure Research, 2017, 42, 509-518.	2.0	3
193	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney and Blood Pressure Research, 2019. 44. 1493-1505.	2.0	3
194	Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring. Journal of Chemotherapy, 2022, 34, 149-156.	1.5	3
195	Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. Journal of Nephrology, 2021, 34, 1263-1270.	2.0	3
196	Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry. American Journal of Kidney Diseases, 2022, 79, 635-645.	1.9	3
197	Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review. BMJ Open, 2021, 11, e053857.	1.9	3
198	Management of Elderly Patients with Rapidly Progressive Glomerulonephritis. Blood Purification, 2018, 45, 213-217.	1.8	2

#	Article	IF	CITATIONS
199	Assessment of renal function before contrast media injection: right decisions based on inaccurate estimates. European Radiology, 2019, 29, 3192-3199.	4.5	2
200	Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis. Kidney and Blood Pressure Research, 2022, 47, 448-458.	2.0	2
201	The Influence of Pefloxacine on Experimental Adriamycin-Induced Nephrotic Syndrome in Rats. Renal Failure, 1996, 18, 195-199.	2.1	1
202	Unusual manifestation of AL amyloidosis—stenosis of inferior vena cava. Nephrology Dialysis Transplantation, 2006, 21, 1430-1433.	0.7	1
203	Biosimilars and Renal Health Care in the Countries of Central and Eastern Europe. Kidney and Blood Pressure Research, 2007, 30, 2-5.	2.0	1
204	Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 296-303.	1.2	1
205	Moderator's view: Cyclophosphamide in lupus nephritis. Nephrology Dialysis Transplantation, 2016, 31, 1058-1061.	0.7	1
206	Cardiorenal interactions. Cor Et Vasa, 2018, 60, e144-e147.	0.1	1
207	FP275A BIOMARKER OF COLLAGEN TYPE III DEGRADATION DECREASES WITH INCREASING FIBROSIS IN THE KIDNEY OF PATIENTS WITH IgA NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i124-i124.	0.7	1
208	Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?. Nephrology Dialysis Transplantation, 2021, 36, 37-43.	0.7	1
209	Extrarenal complications of granulomatosis with polyangiitis (GPA)Â and microscopic polyangiitis (MPA) and their impact on the outcome of the patients. Journal of Nephrology, 2022, 35, 1065-1068.	2.0	1
210	Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis as a Complication of Home Parenteral Nutrition. Case Reports in Nephrology and Dialysis, 2022, 12, 22-30.	0.6	1
211	CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol. Journal of Vascular Access, 2024, 25, 294-302.	0.9	1
212	Laudatio to Professor Otto Schück on the Occasion of His 80th Birthday. Kidney and Blood Pressure Research, 2006, 29, 327-328.	2.0	0
213	FP124MATRIX METALLOPROTEINASES (MMP-2, 3, 7, 9) AND THEIR TISSUE INHIBITORS (TIMP-1, 2) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Nephrology Dialysis Transplantation, 2015, 30, iii108-iii108.	0.7	0
214	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2016, 31, i45-i46.	0.7	0
215	MP170CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITH PLASMA EXCHANGE IN A SINGLE CENTRE. Nephrology Dialysis Transplantation, 2016, 31, i397-i397.	0.7	0
216	MP207SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AND METALLOPROTEINASE TISSUE INHIBITORS TIMP-1 AND TIMP-2 IN PATIENTS WITH ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2016, 31, i409-i409.	0.7	0

#	Article	IF	CITATIONS
217	SP035THE ROLE OF S100 PROTEINS AND MATRIX METALLOPROTEINASE AND THEIR INHIBITORSIN THE PATHOGENESIS OF LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2018, 33, i357-i358.	0.7	0
218	SP174DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF A PANEL OF SERUM AND URINARY BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
219	185.â€∱GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. Rheumatology, 2019, 58, .	1.9	0
220	118. VALIDATION OF THE RENAL RISK SCORE FOR ANCA-ASSOCIATED GLOMERULONEPHRITIS. Rheumatology 2019, 58, .	' 1.9	0
221	FRI0192â€A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIC FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	ONS	0
222	Nephrology in the Czech Republic. , 2021, , 499-509.		0
223	Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. European Journal of Clinical Pharmacology, 2022, 78, 89-98.	1.9	0
224	Granulomatosis with polyangiitis mimicking cancer: a diagnostic dilemma. Journal of Nephrology, 2022, 35, 675-678.	2.0	0
225	Gliflozins slow down the progression of diabetic kidney disease. Vnitrni Lekarstvi, 2017, 63, 723-727.	0.2	0
226	Pulmonary‑renal syndrome. Vnitrni Lekarstvi, 2020, 66, e20-e25.	0.2	0